We recently demonstrated that CD24 is a crucial CSC marker that is overexpressed in urothelial CSCs.11 It was also reported previously that CD24 acts as a hub of tumorigenesis and metastatic progression, and associated with a poor outcome in UCB.12–15 Moreover, CD24 deficiency reduced urothelial tumorigenesis and metastasis in a mouse model,16 and treatment with an anti-CD24 monoclonal antibody resulted in a decreased metastatic tumour burden.15 Thus, CD24 has been implicated in tumour initiation and progression as an oncogene, and it is a potential therapeutic target for UCB. The gene discussed is CD24; the disease is neoplasm.